Merck (MRK) Short term Debt (2009 - 2026)

Merck has disclosed Short term Debt across 18 years of filings, most recently posting $2.4 billion for Q1 2026.

• In Q1 2026, Short term Debt rose 79.71% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $2.4 billion (up 79.71% YoY), while the FY2025 annual figure was $2.6 billion, down 2.27% from the prior year.
• Short term Debt fell to $2.4 billion in Q1 2026, from $2.6 billion in the prior quarter.
• Over the last five years, Short term Debt for MRK reached as high as $3.1 billion in Q3 2024 and fell as low as $887.0 million in Q3 2023.
• The 5-year median for Short term Debt is $2.4 billion (2026), against an average of $2.2 billion.
• Annual changes were most pronounced in 2022 — Short term Debt slumped 83.34% — and 2024, when it jumped 255.02%.
• A 5-year view of Short term Debt shows it stood at $1.9 billion in 2022, then decreased by 29.5% to $1.4 billion in 2023, then surged by 93.08% to $2.6 billion in 2024, then fell by 2.27% to $2.6 billion in 2025, then dropped by 5.6% to $2.4 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $2.4 billion, $2.6 billion, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.